Trial Profile
Retrospective safety and efficacy analysis of half dose and full dose sorafenib administration in patients with hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Dec 2015 New trial record